Mitochondrial Myopathies: Clinical Trials

79 trials for Mitochondrial Myopathies, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

44 completed, 17 recruiting, 6 unknown, 4 terminated. 25 Phase 2, 16 Not applicable, 12 Phase 1, 4 Phase 3, 2 Early Phase 1.

By phase and status

PhaseTrialsStatus
Phase 225Completed 13, Terminated 4, Unknown 3, Recruiting 2, Active not recruiting 1, Not yet recruiting 1, Suspended 1
Not applicable16Completed 11, Recruiting 2, Active not recruiting 1, Not yet recruiting 1, Unknown 1
Phase 112Completed 7, Recruiting 4, Not yet recruiting 1
Phase 34Completed 2, Recruiting 1, Terminated 1
Early Phase 12Completed 2
Phase 41Completed 1

Follow Mitochondrial Myopathies: new trials by email Literature Review of Mitochondrial Myopathies trials Research Report on Mitochondrial Myopathies

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Basket Clinical Study to Assess Glycerol Tributyrate in Patients With Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like Episodes (MELAS) or Leber's Hereditary Optic Neuropathy-Plus (LHON-Plus)
Glycerol Tributyrate - MELAS Syndrome, Lebers Hereditory Optic Neuropathy With Extra Ocular Symptoms (LHON-Plus)
Phase 1 / Phase 2Not yet recruitingGeorge Washington University242027-03-012026-10-05
Role of AMPKalpha2 in Myonuclear Accretion in Mitochondrial Myopathies
Analysis of signaling pathway : AMPK - MItochondrial Myopathies
Not yet recruitingHospices Civils de Lyon122027-01-012026-11-05
Prospective Natural History Study of POLG Disease
PolG, Primary Mitochondrial Myopathy
RecruitingThe POLG Foundation3002026-06-172026-09-15
KHENERFIN Study: A Trial to Evaluate the Efficacy and Safety of Sonlicromanol in Primary Mitochondrial Diseases
Sonlicromanol, Placebo - Mitochondrial Diseases, Maternally Inherited Diabetes and Deafness (MIDD)
Phase 3RecruitingKhondrion BV2202026-04-142026-10-14
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
Whole-body Electrical Muscle Stimulation Exercise - Neuromuscular Diseases (NMD), Amyotrophic Lateral Sclerosis
Not applicableActive not recruitingUniversity of Missouri-Columbia502026-03-102026-11-06
Exercise Training Effects on Muscle Function in Adults With Mitochondrial Myopathy
Unilateral high-intensity interval training (HIIT) - Mitochondrial Diseases, Mitochondrial Myopathy
Not applicableRecruitingUniversity of Copenhagen222026-01-092026-03-05
An Open-label Extension Safety Study of MELAS Patients Who Completed TIS6463-203 (PRIZM)
zagociguat 15mg - Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome)
Phase 2TerminatedTisento Therapeutics372025-08-182026-11-06
A Study to Assess TTI-0102 vs Placebo in MELAS Patients
TTI-0102, Placebo - MELAS Syndrome, Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like Episodes (MELAS)
Phase 2CompletedThiogenesis Therapeutics, Inc.92025-05-122026-07-24
Validation of Nanosensor Oxygen Measurement
Nanosensor - MItochondrial Myopathies, Mitochondrial Disease
Phase 1RecruitingChildren's Hospital of Philadelphia702025-01-022026-10-07
Doxecitin and Doxribthymine in Adult Subjects With Thymidine Kinase 2 (TK2) Deficiency
Doxecitine and Doxribtimine - Thymidine Kinase 2 (TK2 ) Deficiency, Mitochondrial Myopathies
Phase 2RecruitingCristina Domínguez González152025-01-012026-09-17
Exercise-mediated Rescue of Mitochondrial Dysfunctions Driving Insulin Resistance
High-intensity exercise training - Mitochondrial Myopathies, Mitochondrial Diseases
Not applicableCompletedCopenhagen University Hospital, Rigshospitalet112024-09-222025-06-22
A Phase 2b Study of Zagociguat in Patients With MELAS
zagociguat 15mg, zagociguat 30mg, Placebo - Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome)
Phase 2CompletedTisento Therapeutics432024-09-102026-10-23
Patterns of Neurodevelopmental Disorders
Neurodevelopmental Disorders, Autism Spectrum Disorder
RecruitingRichard Frye10002024-02-012026-04-16
Mitochondrial Dysfunctions Driving Insulin Resistance
Mitochondrial Myopathies, Mitochondrial Diseases
CompletedCopenhagen University Hospital, Rigshospitalet302023-10-202025-06-22
Human Mitochondrial Stress-driven Obesity Resistance
Mitochondrial Diseases, Mitochondrial Myopathies
CompletedCopenhagen University Hospital, Rigshospitalet302023-10-202025-06-22
Promoting Resilience in Stress Management (PRISM) and Clinical-focused Narrative (CFN) Pilot in Adults With Primary Mitochondrial Disease (PMD).
Promoting Resilience in Stress Management (PRISM), Clinical-focused narrative (CFN) - Mitochondrial Diseases, Mitochondrial Myopathies
Phase 1 / Phase 2CompletedChildren's Hospital of Philadelphia162023-09-222024-11-29
Effectiveness of Ketogenic Diet in MELAS Syndrome
Ketogenic diet - MELAS Syndrome, Ketogenic Dieting
Not applicableNot yet recruitingSecond Affiliated Hospital, Zhejiang University, School of Medicine1002023-09-012023-08-28
Effect and Safety MABs Administration m.3243A>G Mutation Carriers
Intra-arterial delivery of autologous MABs - Mitochondrial Myopathies
Phase 2UnknownMaastricht University202023-08-012024-04-15
Study of N-acetylcysteine in the Treatment of Patients With the m.3243A>G Mutation and Low Brain Glutathione Levels
N-Acetylcysteine - Mitochondrial Disease
Phase 1RecruitingMichio Hirano, MD182023-07-062026-01-23
Mitochondrial Video Assessment Source Material Study
PolG, Primary Mitochondrial Myopathy
CompletedThe Emmes Company, LLC282023-06-162024-11-14

Showing 20 of 79. Sign in to see all of them.

Narrower conditions

MELAS Syndrome (37)  ·  Mitochondrial Diseases (34)  ·  Ophthalmoplegia, Chronic Progressive External (12)  ·  Leigh Disease (10)  ·  Mitochondrial Encephalomyopathies (9)  ·  Acidosis, Lactic (8)  ·  MERRF Syndrome (6)  ·  Kearns-Sayre Syndrome (5)  ·  Mitochondrial encephalopathy (5)  ·  Muscular Diseases (5)  ·  Neuromuscular Diseases (4)  ·  Noninsulin-dependent diabetes mellitus with deafness (4)  ·  Seizures (4)  ·  Deafness (3)

Broader conditions

Metabolic Diseases (79)  ·  Musculoskeletal Diseases (79)  ·  Nervous System Diseases (79)  ·  Nutritional and Metabolic Diseases (79)  ·  Neuromuscular Diseases (75)  ·  Muscular Diseases (74)  ·  Central Nervous System Diseases (47)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (47)  ·  Genetic Diseases, Inborn (46)  ·  Brain Diseases (45)  ·  Mitochondrial Diseases (45)  ·  Brain Diseases, Metabolic (44)  ·  Metabolism, Inborn Errors (42)  ·  Brain Diseases, Metabolic, Inborn (41)  ·  Cardiovascular Diseases (40)

Interventions

6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (4)  ·  alpha-tocotrienol quinone (3)  ·  arginyl-2,'6'-dimethyltyrosyl-lysyl-phenylalaninamide (3)  ·  Arginine (2)  ·  Cysteamine (2)  ·  Niacin (2)  ·  nicotinamide-beta-riboside (2)  ·  Acetylcysteine (1)  ·  Bulk Drugs (1)  ·  Citrulline (1)  ·  Deoxycytidine (1)  ·  Dichloroacetic Acid (1)  ·  Diet, Ketogenic (1)  ·  Exercise (1)  ·  Exercise Test (1)

Sponsors

Copenhagen University Hospital, Rigshospitalet (6)  ·  Khondrion BV (6)  ·  Children's Hospital of Philadelphia (5)  ·  Columbia University (4)  ·  Stealth BioTherapeutics Inc. (4)  ·  Maastricht University (3)  ·  PTC Therapeutics (3)  ·  Tisento Therapeutics (3)  ·  Amgen (2)  ·  Baylor College of Medicine (2)  ·  Institut de Myologie, France (2)  ·  National Center for Research Resources (NCRR) (2)  ·  The Hospital for Sick Children (2)  ·  University of Helsinki (2)  ·  Abliva AB (1)

Countries

United States (42)  ·  Denmark (13)  ·  Netherlands (12)  ·  United Kingdom (12)  ·  Germany (9)  ·  Italy (9)  ·  France (8)  ·  Spain (8)  ·  Canada (7)  ·  Australia (5)  ·  Finland (2)  ·  Hungary (2)  ·  Japan (2)  ·  Norway (2)  ·  Poland (2)

Top investigators

Michio Hirano, MD (5)  ·  John Vissing, MD (3)  ·  Matteo Fiorenza, Ph.D. (3)  ·  Vinay Penematsa, MD (2)  ·  Amel Kaara (1)  ·  Andreas Schulze, MD (1)  ·  Anne Chiaramello, Ph.D. (1)  ·  Anu Suomalainen Wartiovaara, MD, PhD (1)  ·  Anu Suomalainen Wartiovaara, MD,PhD (1)  ·  Chad Glasser, PharmD (1)  ·  Cornelia L Dekker, MD (1)  ·  Darryl C De Vivo, MD (1)  ·  Debra Regier, M.D., Ph.D. (1)

Results publications

PMID 11182283, PMID 12013896, PMID 12508073, PMID 12771225, PMID 12826641, PMID 15090651, PMID 15684706, PMID 16621917, PMID 16971696, PMID 16971699, PMID 17080429, PMID 17353390, PMID 17483096, PMID 17486094, PMID 17549623, PMID 18238797, PMID 18467430, PMID 18546365, PMID 19103785, PMID 19125351, PMID 19138848, PMID 19192035, PMID 19667227, PMID 19766516, PMID 19889013, PMID 20301762, PMID 20301791, PMID 20329599, PMID 20444604, PMID 21483760, PMID 21774628, PMID 21855607, PMID 22084276, PMID 22176657, PMID 22608879, PMID 22711161, PMID 23168274, PMID 23169334, PMID 23230576, PMID 23385875, PMID 23714749, PMID 23817075, PMID 245993, PMID 24708634, PMID 24985751, PMID 25857492, PMID 25993630, PMID 26342080, PMID 26760297, PMID 27554452

NIH funding

U54NS078059 (4), P01HD032062 (2), K01HD084690 (1), R01AR050597 (1), R01AR083552 (1), R01EY029437 (1), R21HD061709 (1), UH3TR003897 (1)